Gingival crevicularfluid osteoprotegerin levels in Indian population by Bandari, Purnima et al.
Dental Research Journal
Dental Research Journal  /  November 2012  /  Vol 9  /  Issue 6774
Original Article
Gingival crevicularfluid osteoprotegerin levels in Indian population
Purnima Bandari1, M. V. Ramachandra Prasad1, Arun Maradi2, A. R. Pradeep1, Mallika A.1, Dileep Sharma1
1Department of Periodontics, Government Dental College and RI, Bengaluru, Karnataka, 2Department of Periodontics, Koyamattur Dental College 
and RI, Kerala, India
ABSTRACT
Background: Initial research indicated that higher concentration of osteoprotegerin (OPG) is 
associated with healthy periodontium (protective) and its concentration decreases as the periodontal 
disease progresses. However, till date, there are no studies to investigate the levels of OPG in 
gingival crevicular fluid (GCF) after the treatment of periodontitis. Hence, the present study was 
carried out to assess its concentration in GCF to find out their association if any, and to explore 
its possible use as a ‘novel bone marker’ of the host modulation of periodontal disease.
Materials and Methods: Sixty‑four subjects were divided into 4 groups (16 each), based on clinical 
attachment loss (CAL) and radiological parameters (bone loss); healthy (group I), gingivitis (group II), 
slight periodontitis (group III), and moderate‑to‑severe periodontitis (group IV). Moderate‑to‑severe 
periodontitis subjects, after nonsurgical periodontal treatment, (SRP) constituted group V. GCF 
samples were collected to estimate the levels of OPG using enzyme‑linked immunosorbent assay 
(ELISA). The Kruskal‑Wallis, Man‑Whitney U test, and Wilcoxon signed‑rank tests were carried out 
to compare OPG levels among groups. The Spearman rank correlation test was used to correlate 
OPG levels between the study groups and the clinical parameters; P < 0.05 was considered significant.
Results: The highest mean OPG concentration in GCF was obtained for group I 
(162.47 ± 51.171 pg/ µL) and the least for group IV (10.92 ± 1.913 pg/µL), suggesting a negative 
correlation between OPG concentration and CAL. OPG concentrations in GCF after the treatment 
of group IV increased from 10.92 ± 1.913 pg/µL to 15.63 ± 4.679 pg/µL.
Conclusion: OPG concentration in GCF was inversely proportional to CAL and not an active 
progression factor for periodontal disease. Further, after the treatment of moderate‑to‑severe 
periodontitis subjects (group IV), OPG concentrations increased. Hence, it can be concluded that 
OPG could be considered as a 'novel bone marker' the host modulation of periodontal disease.
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INTRODUCTION
Periodontitis, a chronic inflammatory disease, is 
characterized by increased expression of various 
cytokines and other inflammatory mediators resulting 
in extensive osteoclast formation and bone loss.[1,2] 
These cytokines affect bone remodeling and play a 
vital role in both the physiological and pathological 
regulation of bone.[2,3]
Bone is the specialized connective tissue comprising 
various cells collagenous and inorganic matrix. The 
level of bone mass which is essential to execute 
various functions is maintained by a balanced act 
of bone formation and bone resorption.[4] This 
process is highly co‑ordinated and regulated by two 
specialized cells, osteoblasts, the bone‑forming cells 
and osteoclasts, the bone‑resorbing cells. These cells 
are controlled by various hormones, inflammatory 
mediators, cytokines, and growth factors.[4,5] Recent 
addition to these regulators is the multifactorial 
cytokine OPG which has been detected in GCF.[5,6]
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OPG, a key physiological inhibitor of osteoclastic 
bone resorption,[7] is a glycoprotein which belongs 
to the tumor necrosis factor receptor (TNF) super 
family. [5] It is a decoy receptor for receptor activator 
nuclear factor kappa–B ligand (RANKL)[5] and 
inhibits cell‑to‑cell signaling between marrow stromal 
cells and precursors of osteoclast.[5,8] Thus, it prevents 
the bone resorption by RANKL, which is a precursor 
for the production of osteoclasts.[5]
OPG is expressed by various cell types like 
osteoblasts, osteoclastic stromal cells, T cells, B cells, 
chondrocytes, and follicular dendritic cells.[9] However, 
it is also found in organs like the kidney, liver, heart, 
lung, spleen, thyroid, lymph nodes, thymus, brain, and 
placenta.[5] It is also found in periodontal and dental 
tissues like gingiva and periodontal ligament,[10] both 
in the internal and the external enamel epithelium, 
as well as in the mesenchyme of the dental papilla 
during tooth development.[11] Moreover, a prominent 
expression of OPG in the cartilaginous primordia of 
developing maxilla, mandible, and hyoid bone has 
been reported.[5]
Further, OPG has been reported to have a preventive 
role in rheumatoid arthritis‑associated bone erosion 
in joints[12] and its deficiency in inflamed joints of 
rheumatoid arthritis confirms this finding.[13]
Recently, OPG was isolated in gingival tissue[14] and 
GCF[15] with its levels decreasing with the progression 
of periodontal diseases suggesting that OPG levels in 
GCF may become a modulator of periodontal disease, 
especially alveolar bone resorption.[6,15]
However, till date, there have been no studies on the 
correlation of OPG levels in GCF during periodontal 
health, disease, and after nonsurgical periodontal 
therapy (SRP).
Hence in the light of the aforementioned facts, this 
clinico‑biochemical study was designed to estimate 
the levels of OPG in the GCF of subjects with 
clinically healthy periodontium, gingivitis, slight 
periodontitis, moderate‑to‑severe periodontitis, and of 
moderate‑to‑severe periodontitis subjects after scaling 
and root planing (SRP).
MATERIALS AND METHODS
This study conducted during the period from August 
to September 2007 involved 64 subjects (32 females, 
32 males) aged 30‑39 years selected from the 
outpatient section, Department of Periodontics, 
Government Dental College and Research Institute, 
Bengaluru, Karnataka, India. Essential ethical 
clearance for the study was obtained from the 
institutional ethical review board, Government 
Dental College and Research Institute, Rajiv Gandhi 
University of Health Sciences, Karnataka, India. 
Those who volunteered were briefed about the 
study procedure, and a consent form was signed on 
acceptance by them.
Specific conditions that excluded participation in the 
study were (i) pregnant, lactating, and postmenopausal 
women, (ii) patients with diabetes mellitus, ischemic 
heart disease, or any other conditions contributing to 
atherosclerosis, malignant tumors, rheumatoid arthritis, 
bone disorders, and/or on cancer chemotherapy or those 
on antiresorptive drugs like bisphosphonates, With 
this disese will hve OPG concentration less because 
of infl ammation, (iii) smokers and alcoholics, (iv) 
subjects who received treatment with anti‑inflammatory 
drugs, antibiotics, steroids, or contraceptives in the last 
six months, and (v) those receiving any periodontal 
treatment.
The subjects were categorized into groups, each group 
comprising 16 patients based on modified gingival 
index (MGI)[16] and clinical attachment loss (CAL)[17] 
with radiographic evidence of bone loss.
Group I (healthy): Consisted of 16 subjects with 
clinically healthy periodontium and with no evidence 
of disease. The score obtained after assessing the 
gingival status using MGI was zero and with no crestal 
bone loss as determined from the radiograph. Group II 
(gingivitis): Consisted of 16 subjects whose gingivae 
showed clinical signs of inflammation but there was 
no evidence of CAL, which was zero. The intraoral 
periapical radiographs did not show any bone loss. 
A score between 1 and 2 was obtained after recording 
MGI. Group III (slight periodontitis): Consisted of 
16 subjects, who showed clinical signs of gingival 
inflammation and CAL of 1‑2 mm with radiographic 
evidence of bone loss. MGI score between 2 and 4 
was obtained for these patients. Group IV (moderate 
to severe periodontitis): Consisted of 16 subjects, who 
showed clinical signs of gingival inflammation and 
CAL >3 mm with radiographic evidence of bone loss. 
MGI score between 2 and 4 was obtained for these 
patients. Group V (after‑treatment group): Consisted 
of group IV subjects treated nonsurgically, and GCF 
samples were collected from the same sites six to 
eight weeks after treatment, to constitute group V 
[Figures 1‑5].
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Figure 1a: Clinical picture of a patient of Group I (Healthy) 
showing CAL of 0 mm on the mesiolabial aspect of 11
Figure 2a: Clinical picture of a patient of Group II (Gingivitis) 
showing CAL of 0 mm on the mesiolabial aspect of 11
Figure 3a: Clinical picture of a patient of Group III (Slight 
periodontitis) showing CAL of 1-2 mm on the mesiolabial 
aspect of 21
Figure 1b: Radiographic picture of same area
Figure 2b: Radiographic picture of same area
Figure 3b: Radiographic picture of same area
Site selection and fluid collection
The sampling protocol was followed as described 
previously in the earlier studies by the group. [18] 
Briefly, clinical and radiological examinations, 
group allocation, and sampling‑site selections were 
performed by one examiner (PB) and the samples 
were collected on the subsequent day by the second 
examiner (MVRP). This was done to ensure blinding 
of the sampling examiner and to prevent contamination 
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Figure 4a: Clinical picture of a patient of Group IV (moderate 
to severe periodontitis) showing CAL of >3 mm on the 
mesiobuccal aspect of 46
Figure 5a: Clinical picture of a patient of Group V (moderate 
to severe periodontitis after treatment)
Figure 4b: Radiographic picture of same area
Figure 5b: Radiographic picture of same area after treatment
of GCF with blood associated with the probing of 
inflamed sites. Only one site per subject was selected 
as a sampling site. In the healthy group, sampling 
was predetermined to be from the mesiobuccal region 
of the maxillary right or left first molar, wherever 
adequate sample was obtainable. In gingivitis, sites 
with the highest clinical signs of inflammation 
were selected. In periodontitis, sites with 1‑6 mm 
CAL were identified using a Williams graduated 
periodontal probe followed by radiographical 
confirmation of bone loss and assigned for sampling. 
On subsequent day, a standardized volume of 1 mL 
GCF was collected from each predetermined test 
site using the calibration on color‑coded 1‑5 mL 
calibrated volumetric microcapillary pipettes* with an 
extracrevicular approach (unstimulated). Plastic vials 
were used to store the GCF‑containing micropipettes 
and stored at −70°C until the assay [Figures 6 and 7].
*  Sigma Aldrich Chemicals Company Limited, USA.
Osteoprotegerin assay
After appropriate dilution of GCF samples, a 
sandwich type of ELISA Development Kit† (ELISA: 
enzyme‑linked immunosorbent assay) was employed 
for the quantitative determination of human OPG 
[Figures 8 and 9].
The 96 well‑plate kit was prepared the previous day 
and incubated overnight, as per the manufacturer’s kit 
development instructions. The kit utilizes a capture 
antibody which was coated on a microtiter plate for 
immobilization and to bind the human OPG in the 
standards or sample. Then, 100 µL of diluted sample 
and standards were added to appropriate wells and 
covered with adhesive strips followed by incubation 
for two hours at room temperature. Later, 100 µL 
(each) of working dilution of streptavidin‑horseradish 
peroxidase (HRP) and substrate solution were added 
†  Human Osteoprotegerin/TNFRSF11B DuoSet, 
R&D Systems, USA.
www.mui.ac.ir
Bandari, et al.: GCF OPG levels in Indian population 
Dental Research Journal  /  November 2012  /  Vol 9  /  Issue 6778
to each well, after washing the plate three times with 
wash buffer between each addition, and incubated for 
20 minutes at room temperature. Finally, 50 µL of 
stop solution was added to each well to stop enzyme 
reaction and the color generated was read at 450 nm. 
The concentration of OPG in the tested samples was 
calculated using the standard curve plotted using the 
optical density values with the standards [Figure 10].
Statistical analysis
A statistical software program was applied to analyze 
the data obtained.‡ The Kruskal‑Wallis, Man‑Whitney 
U test, and Wilcoxon signed‑rank tests were carried 
out to compare OPG levels among groups. The 
Spearman rank correlation test was used to correlate 
OPG levels between the study groups and the clinical 
parameters.
RESULTS
All the GCF samples assayed showed the presence 
of OPG. The highest mean OPG concentration was 
noted in group I (162.47 ± 51.17 pg/µL) and lowest in 
group IV, that is, 10.92 ± 1.91 pg/µL with intermediate 
values for group II (41.39 ± 16.64 pg/ µL), 
‡  Systat® version 11 & SigmaStat®, Systat Software, 
Inc CA, USA.
Figure 6: The microcapillary pipettes with aspirator tube
Figure 8: DuoSet Human  OPG ELISA KIT
Figure 7: Collection of GCF using extra-crevicular positioning 
of microcapillary pipette
Figure 9: Contents of OPG ELISA kit
Figure 10: OPG  capture Antibody preparation
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group III (23.40 ± 1.99 pg/ µL), and group V 
(15.63 ± 4.68 pg/ µL). These results are shown in 
Table 1 and Figure 11.
The results of Kruskal Wallis test (nonparametric), 
carried out to evaluate the difference in OPG levels 
with 5% level of significance (P < 0.05), suggested 
that the mean concentration of OPG differed 
significantly among the groups tested [Table 2].
Further, multiple comparison using Mann‑Whitney U 
test carried out to find the pair or pairs of groups that 
differed significantly (P < 0.05) suggested that OPG 
levels in GCF decreased progressively from health to 
severe periodontitis [Table 3].
When group IV (moderate to severe periodontitis) 
and group V (after treatment of group IV) were 
compared using Wilcoxon signed‑rank test [Table 4], 
the difference in the concentration of OPG was 
statistically significant (P < 0.05), indicating that 
after SRP, OPG levels increased considerably in GCF 
(10.92 pg/µL to 15.63 pg/µL).
Spearman's rank correlation test was done to observe 
any correlation between the GCF OPG concentration 
and clinical variables (MGI and CAL). When OPG 
levels in GCF were tested for correlation with the 
disease severity measures, that is, MGI (in group I 
and II) and MGI and CAL (in groups III, IV, and V), 
a negative correlation was found for GCF OPG 
concentration as shown in Table 5.
When Kruskal Wallis test was done to compare 
the mean OPG concentration in GCF at different 
CAL levels (before and after treatment), there was 
a significant reduction of CAL after treatment, 
which was proportional to a statistically significant 
(P < 0.05) increase of OPG levels in GCF as shown 
in Table 6.
In summary, the mean rank for the group I is the 
highest and it differs significantly from group II, III, 
Table 1: Mean OPG concentration of the study 
groups
Study group Mean±SD Min Max
Group I 162.47±51.171 100.00 300.40
Group II 40.27±16.639 21.25 70.00
Group III 23.40±1.989 20.20 23.25
Group IV 10.92±1.913 8.12 10.91
Group V 15.63±4.679 10.73 15.38
OPG: Osteoprotegerin, SD: Standard deviation, Min: Minimum,  
Max: Maximum

















Comparing the OPG levels among study groups in GCF
Group I Group II Group III Group IV Group V
Table 2: Kruskal‑Wallis test comparing mean GCF 
OPG levels between groups
Study group Mean rank P value





Significant at P < 0.05, OPG: Osteoprotegerin, GCF: Gingival crevicular fluid
Table 3: Pairwise comparison using Mann‑Whitney 
U test for GCF OPG 
Study group Mean rank Z value P value
Group I 24.38 −4.756 0.00*
Group II 8.63
Group I 24.38 −4.842 0.00*
Group III 8.50
Group I 24.38 −4.827 0.00*
Group IV 8.50
Group I 24.38 −4.829 0.00*
Group V 8.50
Group II 19.56 −1.873 0.00*
Group III 13.44
Group II 24.50 −4.833 0.00*
Group IV 8.50
Group II 24.19 −4.650 0.00*
Group V 8.81
Group III 24.50 −4.845 0.00*
Group IV 8.50
Group III 24.19 −4.661 0.00*
Group V 8.81
P < 0.05 significant, OPG: Osteoprotegerin, GCF: Gingival crevicular fluid
Table 4: Wilcoxon signed‑rank test comparing GCF 
OPG concentration before and after treatment
Study group n Mean OPG Conc (pg/µL) Z P value
Group IV 16 10.92 -3.516 0.000*
Group V 16 15.63
*P < 0.05 significant, OPG: Osteoprotegerin, GCF: Gingival crevicular fluid, 
Conc: Concentration
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IV, and V. Further, these results indicate that GCF 
OPG concentration decreases from periodontal health 
to disease.
DISCUSSION
Periodontitis, a chronic inflammatory disease, is 
characterized by increased expression of various 
cytokines and other inflammatory mediators resulting 
in extensive osteoclast formation and bone loss.[1] 
These cytokines affect bone remodeling and play a 
vital role in both the physiological and pathological 
regulation of bone.[2]
OPG, a key physiological inhibitor of osteoclastic 
bone resorption,[7] is a glycoprotein which belongs 
to the TNF super family.[5] It is a decoy receptor 
for RANKL[5] and inhibits cell‑to‑cell signaling 
between marrow stromal cells and precursors of 
osteoclasts. [9] Thus it prevents the bone resorption 
by RANKL, which is a precursor for the production 
of osteoclasts.[6]
OPG is expressed by various cell types like 
osteoblasts, osteoclastic stromal cells, T cells, B 
cells, chondrocytes, and follicular dendritic cells.[9] 
Moreover, it is also found in organs and tissues like 
the kidney, liver, heart, lung, spleen, thyroid, lymph 
nodes, thymus, brain, and placenta.[5] It is found also 
in periodontal and dental tissues like gingiva and 
periodontal ligament and in both internal and external 
enamel epithelium as well as in the mesenchyme 
of the dental papilla during tooth development.[10,11] 
There is a prominent expression in the cartilaginous 
primordia of developing maxilla, mandible, and hyoid 
bone.[5]
Earlier, Mogi et al. correlated OPG concentration in 
GCF and explained its possible role in periodontal 
disease progression.[6] However, till date no other 
studies have been documented that have compared 
the OPG levels in GCF of subjects with healthy and 
diseased periodontium, and those after SRP.
Hence, the present study was undertaken to determine 
the potential role of OPG as a ‘novel bone marker’ 
of periodontal disease modulator. To achieve this 
objective, OPG levels in GCF were quantified and 
compared from healthy, gingivitis, slight periodontitis, 
and moderate‑to‑severe periodontitis subjects, and 
from moderate‑to‑severe periodontitis subjects after 
treatment.
In our study, the mean concentrations of OPG in 
GCF were found to decrease progressively from 
162.47 ± 51.171 pg/µL in healthy subjects to 8.12 pg/ µL 
in periodontitis subjects, whereas in gingivitis, mean 
concentration of OPG was 60.50 pg/ µL. The results of 
the present study, with respect to the general trend, are 
in accordance with those of Mogi et al. who reported 
decreasing OPG levels in GCF with the progression of 
periodontal disease.[6]
When pairwise comparison was done between healthy 
and gingivitis group, gingivitis and slight periodontitis 
group, slight periodontitis and moderate‑to‑severe 
periodontitis group, and moderate‑to‑severe 
Table 5: Kruskal ‑Wallis test comparing CAL and OPG concentrations
Groups CAL level n Mean±Std. Deviation Minimum Maximum F P value
Group III 1 9 23.82±2.42 21.250 30.000 0.939 0.349
2 7 22.85±1.18 20.200 23.700
Group IV 3 4 12.57±0.45 12.025 13.125 26.419 0.000*
4 4 12.79±0.95 12.025 14.000
5 5 9.14±0.65 8.125 9.800
6 2 9.20±0.28 9.000 9.400
7 1 9.20 9.200 9.200
Group V 1 3 20.13±1.15 18.950 21.250 145.623 0.000*
2 5 20.08±1.17 18.900 21.250
3 6 11.01±0.31 10.737 11.400
4 2 11.63±0.33 11.400 11.875
* Significant P < 0.05, OPG: Osteoprotegerin, CAL: Clinical attachment loss
Table 6: Results of Spearman’s rank correlation 
(r) test comparing GCF OPG and CAL within the 
groups
Groups CAL vs. OPG correlation P value
Group III -0.251 0.349
Group IV -0.794** 0.000*
Group V -0.846** 0.000*
*Significant P < 0.05, **negative correlation OPG: Osteoprotegerin, 
GCF: Gingival crevicular fluid, CAL: Clinical attachment loss
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periodontitis group and after‑treatment group, 
healthy and slight periodontitis group, healthy and 
moderate‑to‑severe periodontitis group, and healthy 
and moderate‑to‑severe periodontitis group after 
treatment, the differences were statistically significant 
in GCF OPG concentration. The mean rank obtained 
for moderate to severe periodontitis (12.50 pg/µL) was 
very much lower than that of healthy (72.50 pg/ µL), 
gingivitis (52.44 pg/µL), and slight periodontitis 
(44.16 pg/µL) groups. The results were significant 
at P < 0.05. This suggests that OPG levels in GCF 
decrease progressively from health to periodontitis.
In the present study, influence of age and sex of 
the subjects on the OPG levels was minimized by 
selecting the subjects within the narrow age group 
of 30‑39 years and including equal number of male 
and female subjects in each group. Further, this study 
comprised five groups (healthy, gingivitis, slight 
periodontitis, moderate‑to‑severe periodontitis, and 
moderate‑to‑severe periodontitis after treatment) as 
compared to the previous study (Mogi et al. 2004)
where only four groups namely, healthy controls, 
slight periodontitis, moderate periodontitis, and 
severe periodontitis subjects were included, having 
no provision to evaluate the effect of periodontal 
therapy on OPG levels in GCF which can further 
confirm the role of OPG in the modulation of 
periodontal disease.
The levels of OPG reported by the earlier study were 
expressed as ‘amount of OPG’ in pg/µL/site and the 
levels were higher than those of our study. The mean 
of OPG levels of our study are half the concentration 
of OPG levels of the previous study. The reasons for 
these variations in the levels of OPG may be due to 
difference of study population, environmental factors, 
and volume of bone present during the time of GCF 
collection. Due to these reasons, the numerical values 
of OPG from the earlier study are not comparable 
with our study.
The variability of OPG concentration in each group 
could be due to different stages of the disease process 
at the time of collection of GCF. The levels of OPG 
are low in the gingivitis group (group II) compared 
to the healthy group, which could be due to near 
conversion of gingivitis lesion to periodontitis lesion 
that is not detectable clinically either by manual 
probing or radiography. In the slight periodontitis 
group, the OPG concentration was less than that of 
healthy and gingivitis groups.
The moderate‑to‑severe periodontitis subjects were 
treated by SRP, and strict measures of oral hygiene 
were instituted. Eight weeks after the treatment, 
the GCF samples were collected from group IV 
(group V). The mean concentration of OPG in 
GCF in the moderate‑to‑severe periodontitis group 
increased from 10.92 pg/µL before treatment to an 
after‑treatment level of 21.25 pg/µL, respectively, 
which was statistically significant. Recently, similar 
results were reported when gingival biopsies were 
quantified for OPG mRNA (mRNA: messenger RNA) 
and RANKL in healthy and chronic periodontitis 
patients (after SRP).[14]
Most of the samples of group V (after treatment) fall 
between group III (slight periodontitis) and group IV, 
which could be due to modulation of the periodontal 
disease by OPG where it protects the bone by 
preventing osteoclastogenesis accelerated by RANKL.
In our study, the mean MGI scores of periodontitis 
subjects before and after treatment were 2.27 and 
1.34, respectively, which commensurate with those of 
the CAL levels and OPG levels in GCF.
In summary, our study shows that OPG concentration 
in GCF decreases with progression of periodontal 
disease. Further, this was accompanied with the 
decrease in OPG levels that directly correlated with 
the stage of periodontal disease, that is, the amount 
of bone loss and CAL. Further, treatment aimed 
at arresting the progression of periodontal disease 
resulted in a statistically significant rise in levels of 
OPG in GCF proportionally, confirming its active 
role in periodontal attachment gain. The results of 
the present study, therefore, provide site‑specific 
information on changes in OPG levels as a result of 
periodontal disease and after treatment.
The source of OPG in GCF seems to be from 
neighboring tissues including alveolar bone, gingiva, 
and periodontal ligament in periodontal tissues. [5,10] 
Further, the concentration of OPG in GCF was 
increased after periodontal therapy, thus increasing 
the GCF OPG concentration.
In our study, the mean concentration of OPG in 
group IV (moderate‑to‑severe periodontitis group) 
was 10.92 pg/µL, lower than the concentration 
described in the earlier study.[14] Based on the above 
findings, it can be hypothesized that decreased OPG 
levels due to progressive periodontal disease could 
act a as risk factor for the development of periodontal 
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disease. However, this needs to be confirmed by 
conducting longitudinal, prospective studies involving 
larger sample size.
CONCLUSIONS
The present study shows that the OPG concentration 
in GCF decreases proportionally with the progression 
of periodontal disease, that is, gingival inflammation 
and CAL. Further, treatment aimed at arresting 
the progression of periodontal disease resulted in 
statistically significant increased levels of GCF OPG 
proportionally, confirming its active role in periodontal 
attachment gain. Therefore, the results of the present 
study provide site‑specific information on changes in 
OPG levels as a result of periodontal disease and after 
treatment. Thus, within the limits of the present study, 
we can conclude that OPG can be considered as a 
‘novel bone marker’ of the modulation of periodontal 
disease.
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